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ABSTRACT
Objectives: The purpose of this study was to identify abuse-related post-marketing reports associated 
with gabapentinoids use in the Middle East and North Africa (MENA) region countries. Methods: A 
retrospective cross-sectional analysis of abuse-related adverse drug event (ADE) reports from the 
Middle East and North Africa (MENA) region. It was performed using the Food and Drug Administration 
Adverse Event Reporting System (FAERS) database from January 2008 through June 2020. Abuse-
related ADE reports for gabapentin and pregabalin were extracted from the FAERS database. 
Descriptive statistics were performed, and the proportional reporting ratio (PRR) was calculated to 
detect disproportional attribution of abuse-related ADEs for gabapentin versus pregabalin. Results: 
We identified 559 all-cause ADE reports for gabapentinoids, including 205 (36.7%) abuse-related ADE 
reports reported to FAERS in the period of analysis. FAERS included 139 (67.8%) pregabalin and 66 
(32.2%) gabapentin abuse-related ADE reports. Among MENA region countries, Turkey (55, 39.6%) 
and Saudi Arabia (34, 23.7%) had the highest number of abuse-related ADE reports for pregabalin. 
The most pregabalin abuse-related ADE reports involved adult male patients. The PRR of pregabalin 
versus gabapentin abuse-related ADE reports was 1.11, indicating that the number of abuse-related 
events was higher for pregabalin compared to gabapentin. Conclusion: Over 200 cases of abuse-
related gabapentinoids events were reported to FEARS from the MENA region in the study period. 
Further studies should assess risk factors and potential programs to reduce gabapentinoids abuse.
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Gabapentinoids (pregabalin and gabapentin) are 
widely prescribed in neurology and psychiatry 
and often prescribed off-label for a range of 
clinical conditions, including alcohol and 
narcotic withdrawal states, non-neuropathic 
pain disorders, and attention deficit hyperactivity 
disorder. Gabapentinoids act as gamma-
aminobutyric acid (GABA) analogs, blocking 
alpha-2- delta subunit-containing voltage-
dependent calcium channels.1 Gabapentin was 
approved by the Food and Drug Administration 
(FDA) for post-herpetic neuralgia and epilepsy 
in 1993. Pregabalin was approved in 2004 for 
neuropathic pain, fibromyalgia, post-herpetic 
neuralgia, and seizures.2-5 In the United States, the 
prescription rates for gabapentinoids increased 
significantly between 2002 and 2015 and 
pregabalin was a top 10 best-selling medication 
in 2017.6,7 In Saudi Arabia, pregabalin was one of 
the top 10 sold drugs during 2010-2015.8
Recent systematic reviews documented 
gabapentinoid abuse-related adverse drug 
events (ADEs), including abuse, misuse, 
dependence, or overdose.9,10 Studies have also 
shown gabapentinoids are likely to be abused 
among individuals with opioid dependence 
syndrome.11-13 The abuse potential of 
gabapentinoids has been demonstrated in some 
clinical studies.9,10 In Saudi Arabia, a study found 
that 12.4% of participants used pregabalin without 
a prescription.14 Additionally, studies showed 
the potential risks for pregabalin misuse, abuse, 
and related harms in the United Arab Emirates 
and Jordan.15,16 A few case reports also described 
pregabalin abuse in Turkey and Lebanon.17-19
The abuse of gabapentinoids is a serious public 
health problem.6,13,14,16-20 There are some differences 
among countries in terms of gabapentinoids 
scheduling system. According to the United 
States Drug Enforcement Administration (DEA), 
pregabalin is classified as a Schedule V controlled 
substance, representing the least potential for 
abuse. In contrast, gabapentin is not classified 
as a controlled substance despite the evidence 
of abuse.4,5,13 On the other hand, In Saudi 
Arabia, in May 2015, pregabalin was classified 
as a controlled substance by (SFDA). However, 
gabapentin is still a prescribed medication (Saudi 
Food and Drug Authority). The Jordan Food 
and Drug Administration (JFDA) also included 
pregabalin preparations in the restricted drug list 
in 2017.21-23 On the other hand, gabapentinoids 
are not controlled medications in Turkey.17
Although gabapentinoids share many similar 
pharmacologic properties, such as interacting 
with the same binding site, renal excretion, 
comparable metabolic profiles, minimal 
protein binding, and negligible drug-drug 
interactions, they have significant absorption 
differences.24-27 Gabapentin is absorbed less 
rapidly than pregabalin, with maximum plasma 
concentrations attained within 3-4 hr instead of 1 
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hr. Due to saturable absorption, gabapentin absorption drops from 68% 
to 36% after the dosage increases from 300mg to 1600 mg. In contrast, 
pregabalin’s absolute bioavailability maintains ≥90% despite increasing 
doses.24,26,28 That might explain why pregabalin is classified as a controlled 
medication while gabapentin is not. 
A recent study, which used the United States data from the 2012-2016 
Food and Drug Administration Adverse Event Reporting System 
(FAERS) data; found that a total of 576 cases out of 10,038 (5.7%) abuse-
related events were reported to FAERS for gabapentin, and 58 cases out 
of 571 (10.2%) ADEs related to abuse were identified for pregabalin.29
This study has been conducted to evaluate epidemiological information 
regarding the scope of gabapentinoids abuse utilizing the FAERS 
database not to assess their abuse trends. To the authors’ knowledge, there 
were no studies available at the time of this study that have identified 
abuse-related post-marketing reports associated with gabapentinoids 
(gabapentin and pregabalin) use in the Middle East and North Africa 
(MENA) region countries.This study aimed to identify abuse-related 
post-marketing reports associated with gabapentinoids (gabapentin and 
pregabalin) use in the MENA region countries reported to FAERS from 
January 2008 to June 2020.
MATERIALS AND METHODS
Data sources
A retrospective analysis of gabapentinoids (gabapentin and pregabalin) 
ADE reports from the MENA region was performed using the FAERS 
(U.S. Food and Drug Administration). The FAERS database contains 
ADE reports, medication error reports, and product quality complaints 
resulting in adverse events submitted to the FDA. The database is 
designed to support the FDA’s post-marketing safety surveillance 
program for drug and therapeutic biological products. In other words, 
FAERS data play a significant role in identifying early safety signals.30-32
The dataset is publicly available online and de-identified on the FDA 
website. Thus, no institutional review board approval is required. All 
ADE reports for pregabalin and gabapentin reported to FAERS from 
January 2008 to June 2020 were identified by searching the active 
ingredient names, dosage forms, and spellings with no specific reaction 
or outcome criteria. 
The MENA region definition includes 23 countries: Afghanistan, 
Algeria, Bahrain, Djibouti, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, 
Lebanon, Libya, Mauritania, Morocco, Oman, Pakistan, Qatar, Saudi 
Arabia, Somalia, Sudan, Syria, Tunisia, Turkey, United Arab Emirates, 
Yemen. The MENA region reports were extracted by using International 
Organization for Standardization (ISO) 3166-1 alpha-2 codes.33-35
FAERS classifies the reports expedited (reports from the manufacturer 
submitted to the FDA within 15 days of a serious and unexpected ADE 
not included in product labeling) and non-expedited reports of serious 
and non-serious adverse events for new molecular entity (NME) products 
within the first three years following FDA approval.36 Serious outcomes 
include death, hospitalization, life-threatening, disability, congenital 
anomaly, and/or other serious outcomes. The primary sources of FAERS 
reports are categorized into healthcare professionals and consumers. 
Abuse-related ADE reports were defined as reports with drug abuse, drug 
dependence, drug tolerance, withdrawal syndrome, euphoric mood, 
overdose, intentional overdose, intentional product misuse, product use 
in unapproved indication, maternal use an illicit drug, loss of personal 
independence in daily activities, substance-induced psychotic disorder, 
and intoxication.25,29,37-39 The demographic characteristics of FAERS 
reports are limited. ADE reports were classified by patient gender (male, 
female) and age in years at the time of the report.
Data analysisDescriptive statistics were performed, and the proportional 
reporting ratio (PRR) was calculated to detect a disproportional 
attribution of ADEs for gabapentin versus pregabalin. The PRR was 
calculated using the following equation: PRR=[Pa/Pt]/[Ga/Gt], where Pa = 
number of ADEs reported for pregabalin abuse, Pt = total number of ADEs 
reported for all pregabalin, Ga = number of ADEs reported of gabapentin 
abuse, and Gt = total number of ADEs reported for all gabapentin. The 
null value for a PRR is one, which means the higher the PRR, the greater 
the strength of the signal of abuse.29,40 Descriptive statistical analyses, 
including frequencies and percentages, were performed using Microsoft 
Excel (2016 Version, Redmond, WA).
RESULTS
We identified 559 all-cause FAERS ADE reports for gabapentinoids from 
January 2008 to June 2020, including 366 (65.5%) pregabalin and 193 
(34.5%) gabapentin reports. 
FAERS listed 66 (32.2%) abuse-related gabapentin ADE reports, of 
which 55 (83.3%) were reported by healthcare professionals, and 63 
(95.5%) were expedited reports. There were 35 (53.0%) abuse-related 
ADEs reports of women patients. The mean patient age among abuse-
related ADEs was 54.4±16.5 years (median=50). Among MENA region 
countries, Turkey (42, 63.6% of all MENA reports) had the greatest 
number of reports, followed by Iran (17, 25.8%) (Table 1).
The most common gabapentin abuse-related ADEs reactions were 
for indications that are non-FDA approved, which were mentioned in 
16 (23.2%) reports (Table 2). Other gabapentin abuse-related ADEs 
included 15 (21.7%) substance-induced psychotic disorder, 14 (20.3%) 
intoxication, 8 (11.6%) withdrawal syndrome and 8 (11.6%) maternal 
use of illicit drugs reactions. The outcomes reported for gabapentin 
abuse-related ADE included 6 (9.1%) death, 8 (12.1%) hospitalizations, 
and 46 (69.7%) other serious outcomes (Table 3).
Moreover, from January 2008 to June 2020, FAERS listed 139 (67.8%) 
abuse-related pregabalin ADE reports. There were 106 (76.3%) cases 
were reported by healthcare professionals to the FAERS database, and 
137 (98.6%) were expedited reports. There were 67 (48.2%) abuse-related 
ADEs reports of male patients. The mean patient age among abuse-
related ADEs was (36.0 ± 19.1) years (median=28). Among MENA 
region countries, Turkey (55, 39.6%) had the greatest number of reports, 
followed by Saudi Arabia (34, 23.7%) and Jordan (19, 13.7%) (Table 1).
Drug abuse was mentioned in 77 (39.1%) reports and was the most 
frequent pregabalin abuse-related ADE, followed by overdose (24, 
12.2%), intentional overdose (12, 6.1%), and drug dependence reactions 
(12, 6.1%) (Table 2). The outcomes reported for pregabalin abuse-related 
ADE included 4 (2.9%) death, 24 (17.3%) hospitalizations, 2 (1.4%) 
congenital anomalies, and 103 (74.1%) other serious outcomes (Table 3).
The PRR of pregabalin versus gabapentin abuse-related events was 1.11, 
indicating that the number of abuse-related ADEs and the strength of the 
signal of abuse were slightly higher for pregabalin than for gabapentin.
DISCUSSION
This study’s results indicate that most of the gabapentinoids abuse-
related events reported in some of the MENA region countries in the 
study period were associated with pregabalin use. This finding could 
be due to the distinct pharmacokinetic advantages of pregabalin over 
gabapentin. These advantages have been linked to the superiority of 
pregabalin pharmacodynamic properties such as higher bioavailability, 
faster absorption, and rapid onset of action with higher potency than 
gabapentin, which may explain the higher addiction potential of 
pregabalin.24-28We also noted that Turkey, Saudi Arabia, and Jordan 
had the greatest number of pregabalin abuse-related ADE reports 
among MENA region countries. In most MENA region countries, 
gabapentinoids are prescribed as non-controlled medications.16,41 
However, some of the MENA countries have taken serious actions to 
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prevent the risk of gabapentinoids abuse. For instance, in Saudi Arabia, 
the SFDA classified pregabalin as a controlled substance in May 2015, but 
gabapentin has not been classified as a controlled substance yet (Saudi 
Food and Drug Authority). In Jordan, the JFDA added pregabalin to the 
restricted drug list in 2017.21-23Previous studies show that gabapentinoid 
abuse events seem to be more likely in young adults; however, data about 
gender differences are conflicting.10,29,39 Our study found that most of the 
gabapentin abuse-related ADE reports involved adult women patients, 
while the majority of pregabalin abuse-related ADE reports were for 
young adult male patients. 
Some MENA region countries did not report any gabapentinoids 
ADE to FAERS. This may be attributed to variations in policies and 
characteristics of reporting systems in the region because each country 
has its adverse event reporting system. For example, Saudi Adverse 
Event Reporting System (SAERS) was launched by SFDA in March 2009 
to monitor the safety of post-marketed medications. Also, the Turkish 
Pharmacovigilance Center (TUFAM) was established in 2015.42The 
analysis also revealed that abuse-related ADEs were higher for pregabalin 
than gabapentin. This result confirms the findings by Evoy et al. 2019. 
Although this study did not assess the concomitant medications, 
Chiappini et al. 2016 and Evoy et al. 2019 studies found that most deaths 
occurred in patients who were also taken opioids.29,39
This study has some limitations. First, there is no certainty that the ADE 
reports were due to gabapentinoids themselves; it might be due to the 
concomitant medications. Second, since ADE reporting from consumers 
or healthcare professionals is voluntary, the FDA does not receive reports 
for every adverse event or medication error that occurs with a product. 
Therefore, FAERS data can detect safety signals but cannot be used to 
estimate the incidence of adverse events or medication errors. 
CONCLUSION
Over 200 cases of abuse-related gabapentinoids events were reported 
to FEARS from the MENA region in the study period. Further 




Table 1: Characteristics of Gabapentinoids Abuse-Related ADEs  






Total 66 (32.2%) 139 (67.8%)
Male 11 (16.7%) 67 (48.2%)
Female 35 (53.0%) 37 (26.6%)




Standard Deviation ±16.5 ±19.1
Type
Expedited 63 (95.5%) 137 (98.6%)
Non-Expedited 3 (4.5%) 2 (1.4%)
Source
Consumer 11 (16.7%) 33 (23.7%)
Healthcare Professional 55 (83.3%) 106 (76.3%)
MENA Region Countries (Includes Only Countries with FAERS Reports)
Algeria - 7 (5.0%)
Bahrain - 1 (0.7%)
Egypt 1 (1.5%) 3 (2.2%)
Iran 17 (25.8%) 1(0.7%)
Israel 2 (3.0%) 13 (9.4%)
Jordan - 19 (13.7%)
Lebanon 2 (3.0%) 3 (2.2%)
Morocco - 1 (0.7%)
Saudi Arabia 2 (3.0%) 33 (23.7%)
Tunisia - 1 (0.7%)
Turkey 42 (63.6%) 55 (39.6%)
United Arab Emirates - 2 (1.4%)
Table 3: Outcomes of Gabapentinoids Abuse-related ADE Reported to 






TOTAL 66 (32.2%) 139 (67.8%)
Death 6 (9.1%) 4 (2.9%)
Hospitalization 8 (12.1%) 24 (17.3%)
Life-threatening 2 (3.0%) -
Disability 1 (1.5%) -
Congenital anomaly - 2 (1.4%)
Other serious outcomes 46 (69.7%) 103 (74.1%)
Non-serious outcomes 3 (4.5%) 6 (4.3%)
Table 2: Type of Gabapentinoids Abuse-related ADE Reactions  






TOTAL 69 (25.9%) 197 (74.1%)
Drug Abuse - 77 (39.1%)
Overdose 2 (2.9%) 24 (12.2%)
Intentional Overdose - 12 (6.1%)
Drug Dependence 4 (5.8%) 12 (6.1%)
Withdrawal Syndrome 8 (11.6%) 10 (5.1%)
Intentional Product Misuse - 9 (4.6%)
Product Use in Unapproved Indication 16 (23.2%) 9 (4.6%)
Intoxication 14 (20.3%) 8 (4.1%)
Drug Tolerance 1 (1.4%) 6 (3.0%)
Euphoric Mood 1 (1.4%) 4 (2.0%)
Loss of Personal Independence in Daily 
Activities - 4 (2.0%)
Maternal use of the illicit drug 8 (11.6%) 8 (4.1%)
Substance-Induced Psychotic Disorder 15 (21.7%) 14 (7.1%)
*Multiple reactions were listed for some cases
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